PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 239/94, 471/10, 239/70, 405/04, 401/04, A61K 31/505 — A1

(11) International Publication Number: WO 97/14686

(43) International Publication Date: 24 April 1997 (24.04.97)

(21) International Application Number: PCT/GB96/02496

(22) International Filing Date: 14 October 1996 (14.10.96)

(30) Priority Data:

9521231.2	17 October 1995 (17.10.95)	GB
9602668.7	9 February 1996 (09.02.96)	GB
9614386.2	9 July 1996 (09.07.96)	GB

(71) Applicant *(for all designated States except US)*: ASTRA PHARMACEUTICALS LIMITED [GB/GB]; Home Park, Kings Langley, Hertfordshire WD4 8DH (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HAMLEY, Peter, Richard, John [GB/GB]; 25 Fowke Street, Rothley, Leicestershire LE7 7PJ (GB). PIMM, Austen, David [GB/GB]; 19 Rectory Road, Loughborough, Leicestershire LE11 1PL (GB). TINKER, Alan, Charles [GB/GB]; 97 Knightthorpe Road, Loughborough, Leicestershire LE11 5JR (GB). BEATON, Haydn, Graham [GB/GB]; 115 Leicester Road, Quorn, Loughborough, Leicestershire LE12 8BA (GB). McINALLY, Thomas [GB/GB]; 271 Beacon Road, Loughborough, Leicestershire LE11 2RA (GB).

(74) Agent: ENGLAND, Christopher, David; Astra Patents, Astra Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PHARMACEUTICALLY ACTIVE QUINAZOLINE COMPOUNDS

(57) Abstract

Compounds of formula (I) wherein R^1 and R^{19} independently represent hydrogen, alkyl C1 to 6, alkoxy C1 to 6, alkylthio C1 to 6, halogen, hydroxyl or amino; R^2 represent H or alkyl; R^3 represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocylic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1 to 6, alkoxy C1 to 6, halogen, hydroxyl, alkylthio C1 to 6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group $-(CH_2)_c NHCO_2R^{10}$, a group $-(CH_2)_c NR^5R^6$, or a group $-CO_2R^{11}$, or R^3 represents hydrogen or alkyl C1 to 8, which alkyl group may be optionally susbtituted by amino or a group $-NHCO_2R^{10}$; and R^4 represents hydrogen or alkyl C1 to 6; or R^3 and R^4 taken together represent a group $(CH_2)_a Z (CH_2)_b$; c represents an integer 0 to 2; and pharmaceutically acceptable salts thereof, have been found to be useful as a pharmaceuticals. The compounds may especially be used in the treatment of inflammatory disorders.



(I)